Last updated: September 25, 2026
BLOCADREN is the former Merck brand for oral timolol maleate, a nonselective beta blocker approved for hypertension and selected cardiovascular uses. Its commercial trajectory followed a standard mature-drug pattern: initial branded sales, loss of exclusivity, generic substitution, declining clinical use and eventual disappearance as a material revenue contributor. Merck does not report Blocadren revenue separately, and no credible public source supports a standalone sales estimate.
What is Blocadren and who marketed it?
BLOCADREN contains timolol maleate, an orally administered nonselective beta-adrenergic blocker. The product was marketed by Merck under U.S. NDA 018766 and supplied in tablet strengths including 5 mg, 10 mg and 20 mg, according to historical FDA labeling.[1]
| Attribute |
Information |
| Brand |
BLOCADREN |
| Active ingredient |
Timolol maleate |
| Drug class |
Nonselective beta blocker |
| Original sponsor |
Merck & Co. |
| U.S. NDA |
018766 |
| Dosage form |
Oral tablet |
| Historical indications |
Hypertension; post-myocardial-infarction use; migraine prophylaxis in certain labeling |
| Current commercial position |
Legacy or discontinued brand with limited or no material branded sales |
| Principal substitutes |
Generic oral timolol; other beta blockers; ACE inhibitors; ARBs; calcium-channel blockers; migraine preventives |
Timolol is also used in ophthalmic products for glaucoma. Ophthalmic timolol is a separate dosage form and should not be treated as a direct commercial equivalent to oral Blocadren.
When did Blocadren lose exclusivity?
Blocadren lost meaningful branded exclusivity decades ago. The product was approved in the late 1970s, placing its original regulatory exclusivity well before the modern Hatch-Waxman framework became commercially relevant to the product.
FDA’s Orange Book is the principal source for current listed patents and generic-equivalence information. Historical oral timolol products do not represent a current, patent-protected growth franchise. No active, commercially meaningful patent estate is generally associated with the legacy Blocadren brand in the United States.[2]
Exclusivity timeline
| Period |
Commercial development |
| Late 1970s |
FDA approval of oral Blocadren |
| 1980s-1990s |
Branded cardiovascular use with increasing competition from other beta blockers |
| 1990s-2000s |
Generic timolol availability and erosion of brand pricing |
| 2000s-2010s |
Declining clinical use as newer antihypertensive classes gained share |
| 2010s onward |
Legacy product status; limited branded relevance |
| Current |
No meaningful patent-driven exclusivity or branded growth thesis |
Because the product is more than 40 years old, the central market issue is not the timing of a future patent expiry. It is the small and shrinking demand base for oral timolol.
What is the FDA regulatory status of Blocadren?
BLOCADREN is a historical FDA-approved product, but its present commercial availability is limited. FDA labeling identifies oral timolol maleate tablets and provides dosing, contraindications and cardiovascular warnings.[1]
The product’s regulatory value is different from its commercial value. An approved product can remain referenced in FDA databases or historical labeling even when the branded product is no longer actively promoted or distributed at scale.
Key regulatory considerations include:
- Oral timolol carries class risks associated with beta blockade, including bradycardia, hypotension, heart block and bronchospasm.
- Abrupt discontinuation can worsen angina and increase cardiovascular risk in susceptible patients.
- Nonselective beta blockade limits use in patients with asthma or significant reactive airway disease.
- The product is not interchangeable with ophthalmic timolol on a milligram-for-milligram basis.
- Any current manufacturer of generic oral timolol must comply with applicable abbreviated new drug application requirements and current good manufacturing practice standards.
What is the Orange Book status of Blocadren?
The relevant Orange Book analysis is limited because Blocadren is an old small-molecule product with no apparent current patent barrier supporting premium pricing. FDA’s Orange Book identifies listed patents, exclusivity and therapeutic-equivalence information for approved products.[2]
For commercial purposes, the expected patent profile is:
| Patent category |
Blocadren assessment |
| Core compound patent |
Expired |
| Original formulation patent |
Expired or no longer commercially relevant |
| Method-of-use patents |
No material current barrier identified |
| Pediatric exclusivity |
Not commercially relevant to the legacy brand |
| Orphan exclusivity |
Not applicable |
| Biosimilar exclusivity |
Not applicable |
| Current brand exclusivity |
None of material commercial significance |
There is no biologic component to Blocadren, so biosimilar substitution risk does not apply. The relevant competitive threat is generic substitution and therapeutic substitution.
How many patents cover Blocadren?
No meaningful active U.S. patent estate is associated with the legacy Blocadren business. The compound, conventional oral tablet formulation and principal historical uses are long past the period in which patent protection could support branded pricing.
This distinguishes Blocadren from newer beta-blocker products or combination cardiovascular therapies that may have formulation, fixed-dose combination or method-of-use patents. A patent search for current enforcement exposure would focus on any later generic manufacturer patents, manufacturing processes or combination products rather than on the original Blocadren brand.
What generic entry risks exist for Blocadren?
Generic entry risk is effectively realized rather than prospective. Oral timolol is a mature small-molecule product with limited technical complexity and no biologic manufacturing barrier.
Generic competition
The principal sources of erosion are:
- Generic oral timolol maleate tablets.
- Therapeutic substitution to metoprolol, atenolol, carvedilol and other beta blockers.
- Substitution to non-beta-blocker antihypertensives.
- Reduced use of beta blockers as first-line therapy for uncomplicated hypertension.
- Prescriber preference for agents with more selective pharmacology or broader guideline support.
The product has little ability to sustain premium pricing because physicians and pharmacies can select among multiple beta blockers and low-cost generic cardiovascular therapies.
What is the financial trajectory of Blocadren?
Blocadren’s financial trajectory is best described as a long-term decline from branded revenue to negligible or unreported revenue. Merck’s public filings report revenue by broader business segments and major products, not by legacy brands such as Blocadren.[3]
| Financial phase |
Revenue characteristics |
| Branded launch and expansion |
Higher price, physician promotion and Merck distribution |
| Early generic competition |
Rapid price compression and volume migration |
| Mature generic period |
Low unit economics and fragmented supply |
| Late lifecycle |
Limited brand revenue and low strategic priority |
| Current commercial state |
No separately reported material revenue |
No reliable public dataset establishes annual Blocadren sales, current market share or brand-level profitability. Merck’s reporting structure prevents a defensible reconstruction of Blocadren revenue from company filings alone.[3]
Revenue exposure for Merck
Blocadren is not a material driver of Merck’s current revenue exposure. The company’s financial performance is driven by newer pharmaceutical and vaccine franchises, not legacy oral beta blockers.
The economic value of Blocadren to Merck likely declined through four mechanisms:
- Loss of branded price premium.
- Reduced promotional investment.
- Generic substitution.
- Therapeutic displacement by newer cardiovascular treatments.
The product’s residual value would have been limited to continuing supply economics, regulatory maintenance or historical portfolio continuity. Those factors are insufficient to support a standalone investment thesis.
Which companies are challenging Blocadren?
There is no meaningful current Paragraph IV litigation landscape around the legacy brand. Paragraph IV challenges are generally relevant when a generic applicant seeks approval before listed patents expire. Blocadren’s core patent and exclusivity period ended long ago.
Paragraph IV and patent litigation
| Issue |
Current assessment |
| Active Paragraph IV campaign |
No material campaign identified |
| Brand-generic patent litigation |
No material current litigation identified |
| Settlement agreement |
No commercially significant current settlement identified |
| Regulatory exclusivity dispute |
Not material |
| Manufacturing dispute |
No material public dispute identified |
Generic manufacturers historically competed through ANDA pathways, but the commercial significance of those filings is now limited because oral timolol is a mature product.
What formulations are protected by Blocadren?
The original commercial formulation is an immediate-release oral tablet containing timolol maleate. There is no current high-value formulation moat comparable to extended-release delivery systems, depot injections, transdermal systems or complex inhaled products.
The principal formulation risks are operational rather than patent-driven:
- Tablet manufacturing consistency.
- Supply continuity for low-volume strengths.
- API sourcing.
- Stability and dissolution performance.
- FDA compliance at contract or generic manufacturing sites.
These factors can create temporary shortages or supplier exits, but they do not create durable brand pricing power.
How does Blocadren compare with competing beta blockers?
| Product |
Selectivity |
Commercial position |
Competitive impact on Blocadren |
| Timolol oral |
Nonselective |
Legacy generic |
Direct product comparison |
| Propranolol |
Nonselective |
Generic; broader neurologic and cardiovascular use |
Strong therapeutic substitute |
| Metoprolol |
Beta-1 selective |
Widely used generic |
Major substitute in hypertension and cardiac disease |
| Atenolol |
Beta-1 selective |
Mature generic |
Price-based substitute |
| Carvedilol |
Nonselective with alpha blockade |
Generic; heart-failure relevance |
Substitute in selected cardiac patients |
| Bisoprolol |
Beta-1 selective |
Generic or limited-market product |
Alternative in cardiovascular treatment |
Blocadren’s competitive weakness is pharmacologic as well as financial. Nonselective beta blockade can be less attractive than beta-1-selective alternatives for patients with pulmonary risk, while beta blockers generally face competition from other guideline-supported antihypertensive classes.
What is the likely generic launch scenario?
A conventional generic launch scenario has already occurred. A new entrant would face low regulatory complexity but limited commercial upside.
A generic manufacturer would likely evaluate:
- Available FDA-approved reference-product pathway.
- Current API and finished-dose supply.
- Wholesaler and pharmacy demand.
- Reimbursement rates.
- Expected shortage risk.
- Number of active generic competitors.
- Ability to secure a profitable niche in specific strengths.
The main risk is not failure to obtain approval. It is insufficient volume and price compression after approval.
What manufacturing and intellectual-property barriers exist?
Manufacturing barriers are modest. Timolol maleate is a well-established small molecule, and immediate-release tablets are conventional dosage forms. The principal barriers are scale economics, quality compliance and distribution rather than proprietary technology.
Potential operational constraints include:
- Low demand for oral timolol relative to larger cardiovascular products.
- Limited supplier interest in low-volume strengths.
- API qualification and dual sourcing.
- Batch-release costs.
- Retail pharmacy stocking decisions.
- Reimbursement pressure.
These constraints can reduce supply reliability but are unlikely to protect the former brand from competition.
What is the investment outlook for Blocadren?
Blocadren has no identifiable standalone growth thesis. Its market is characterized by:
- Mature generic competition.
- No meaningful remaining brand exclusivity.
- Limited manufacturer promotion.
- Low pricing power.
- No biosimilar or complex-formulation barrier.
- No material public litigation catalyst.
- No separately disclosed Merck revenue stream.
For pharmaceutical investors, Blocadren is best treated as a legacy-product case study rather than an active commercial asset. Any value would depend on niche generic supply, shortage-driven pricing or portfolio aggregation, not on brand expansion.
Key Takeaways
- BLOCADREN is the former Merck brand for oral timolol maleate.
- The product’s U.S. patent and regulatory exclusivity periods ended decades ago.
- Generic and therapeutic substitution have eliminated meaningful branded pricing power.
- Merck does not separately disclose Blocadren revenue.
- No material current Paragraph IV, patent litigation or settlement catalyst is apparent.
- Biosimilar risk does not apply because Blocadren is a small-molecule drug.
- The remaining market opportunity is limited to low-cost generic supply and potential niche availability.
- Financially, Blocadren is a legacy product with negligible identifiable strategic exposure.
FAQs
Is Blocadren still sold in the United States?
The branded product has little or no material current U.S. commercial presence. Oral timolol may remain available through generic or limited-distribution channels, subject to manufacturer and pharmacy supply.
Is Blocadren the same as timolol eye drops?
No. Blocadren is an oral timolol maleate tablet. Timolol ophthalmic products are formulated for ocular administration and are not direct dosage-form equivalents.
Does Merck still earn significant revenue from Blocadren?
No separately reported material revenue is attributable to Blocadren in Merck’s public financial disclosures. The product is commercially insignificant relative to Merck’s current portfolio.
Can a generic company still launch oral timolol?
A generic company may pursue the applicable FDA approval pathway if the reference-product and regulatory conditions support an application. The principal commercial challenge is limited demand and low margins, not patent exclusion.
Is Blocadren a candidate for biosimilar competition?
No. Biosimilars apply to biological products. Blocadren contains the chemically synthesized small molecule timolol maleate and is subject to generic-drug competition.
References
- U.S. Food and Drug Administration. (n.d.). Blocadren (timolol maleate) tablets prescribing information.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Merck & Co., Inc. (n.d.). Annual reports and Form 10-K filings.